Triple negative breast cancer (TNBC), which lacks expression of human epidermal growth factor 2 (HER2) and the hormonal receptors estrogen and progesterone (ER and PR), and HER2+ breast cancer exhibit higher degree of immunogenicity compared to ER+ tumors. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.